These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 23690095)

  • 1. Adaptive adjustment of the randomization ratio using historical control data.
    Hobbs BP; Carlin BP; Sargent DJ
    Clin Trials; 2013; 10(3):430-40. PubMed ID: 23690095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bias in retrospective analyses of biomarker effect using data from an outcome-adaptive randomized trial.
    Ji L; McShane LM; Krailo M; Sposto R
    Clin Trials; 2019 Dec; 16(6):599-609. PubMed ID: 31581815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of the epidemiology methods and applications: strengths and limitations of observational study designs.
    Colditz GA
    Crit Rev Food Sci Nutr; 2010; 50 Suppl 1(s1):10-2. PubMed ID: 21132580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Commensurate Priors for Incorporating Historical Information in Clinical Trials Using General and Generalized Linear Models.
    Hobbs BP; Sargent DJ; Carlin BP
    Bayesian Anal; 2012 Aug; 7(3):639-674. PubMed ID: 24795786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incorporating individual historical controls and aggregate treatment effect estimates into a Bayesian survival trial: a simulation study.
    Brard C; Hampson LV; Gaspar N; Le Deley MC; Le Teuff G
    BMC Med Res Methodol; 2019 Apr; 19(1):85. PubMed ID: 31018832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An efficient Bayesian platform trial design for borrowing adaptively from historical control data in lymphoma.
    Normington J; Zhu J; Mattiello F; Sarkar S; Carlin B
    Contemp Clin Trials; 2020 Feb; 89():105890. PubMed ID: 31740427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic use of historical controls in clinical trials for rare disease research: A re-evaluation of the MILES trial.
    Harun N; Gupta N; McCormack FX; Macaluso M
    Clin Trials; 2023 Jun; 20(3):223-234. PubMed ID: 36927115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Robust meta-analytic-predictive priors in clinical trials with historical control information.
    Schmidli H; Gsteiger S; Roychoudhury S; O'Hagan A; Spiegelhalter D; Neuenschwander B
    Biometrics; 2014 Dec; 70(4):1023-32. PubMed ID: 25355546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian adaptive randomization design incorporating propensity score-matched historical controls.
    Sawamoto R; Oba K; Matsuyama Y
    Pharm Stat; 2022 Sep; 21(5):1074-1089. PubMed ID: 35278032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A group sequential, response-adaptive design for randomized clinical trials.
    Karrison TG; Huo D; Chappell R
    Control Clin Trials; 2003 Oct; 24(5):506-22. PubMed ID: 14500050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian selective response-adaptive design using the historical control.
    Kim MO; Harun N; Liu C; Khoury JC; Broderick JP
    Stat Med; 2018 Nov; 37(26):3709-3722. PubMed ID: 29900577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A simulation study for comparing testing statistics in response-adaptive randomization.
    Gu X; Lee JJ
    BMC Med Res Methodol; 2010 Jun; 10():48. PubMed ID: 20525382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A simulation study of outcome adaptive randomization in multi-arm clinical trials.
    Wathen JK; Thall PF
    Clin Trials; 2017 Oct; 14(5):432-440. PubMed ID: 28982263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilizing shared internal control arms and historical information in small-sized platform clinical trials.
    Jiao F; Tu W; Jimenez S; Crentsil V; Chen YF
    J Biopharm Stat; 2019; 29(5):845-859. PubMed ID: 31462131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials.
    Jiang L; Thall PF; Yan F; Kopetz S; Yuan Y
    Clin Trials; 2023 Oct; 20(5):486-496. PubMed ID: 37313712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel equivalence probability weighted power prior for using historical control data in an adaptive clinical trial design: A comparison to standard methods.
    Bennett M; White S; Best N; Mander A
    Pharm Stat; 2021 May; 20(3):462-484. PubMed ID: 33474798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of adaptive platform trials using a network approach.
    Marschner IC; Schou IM
    Clin Trials; 2022 Oct; 19(5):479-489. PubMed ID: 35993542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting clinical trial results based on announcements of interim analyses.
    Broglio KR; Stivers DN; Berry DA
    Trials; 2014 Mar; 15():73. PubMed ID: 24607270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine.
    Zhou X; Liu S; Kim ES; Herbst RS; Lee JJ
    Clin Trials; 2008; 5(3):181-93. PubMed ID: 18559407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BEATS: Bayesian hybrid design with flexible sample size adaptation for time-to-event endpoints.
    Bi D; Liu M; Lin J; Liu R
    Stat Med; 2023 Dec; 42(30):5708-5722. PubMed ID: 37858287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.